Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells

BACKGROUND: As a highly heterogeneous disease, lung cancer has a multitude of cellular components and patterns of gene expression which are not dependent on a single mutation or signaling pathway. Thus, using combined drugs to treat lung cancer may be a practical strategy. METHODS: The combined anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mi, Quan, Haitian, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046080/
https://www.ncbi.nlm.nih.gov/pubmed/33656275
http://dx.doi.org/10.1111/1759-7714.13902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046080/
https://www.ncbi.nlm.nih.gov/pubmed/33656275
http://dx.doi.org/10.1111/1759-7714.13902

Ejemplares similares